Addressing viral hepatitis C reinfections in a low-threshold programme for people who inject drugs in Slovenia
In marginalised population of PWID attending LTP, a sustainable HCV RNA re-screening and follow-up after HCV cure are necessary, as the risk of reinfection remains high.
Authors
- Maja Pohar Perme (ORCID: https://orcid.org/0000-0002-3412-2642)
- Mojca Matičič (ORCID: https://orcid.org/0000-0003-4261-0424)
- Jelka Meglič Volkar
- Mario Poljak (ORCID: https://orcid.org/0000-0002-3216-7564)
- Jeffrey V. Lazarus (ORCID: https://orcid.org/0000-0001-9618-2299)
- Jasna Černoša (ORCID: https://orcid.org/0000-0003-1570-2999)
Institutions
- The Graduate Center, CUNY (US)
- University of Ljubljana (SI)
- City University of New York (US)
- Ljubljana University Medical Centre (SI)
- Barcelona Institute for Global Health (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Harm Reduction Journal
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1186/s12954-025-01164-5
- Citations
- 3
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Pfizer
- Gilead Sciences
- Centres de Recerca de Catalunya
- Moderna
- Generalitat de Catalunya
- Novo Nordisk
- Javna Agencija za Raziskovalno Dejavnost RS
- Agencia Estatal de Investigación